CHAPEL HILL, N.C., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be making a poster presentation at the European Respiratory Society (ERS) International Congress, being held in Amsterdam from September 26-30, 2015.
Presentation at ERS International Congress:
- A poster presentation will be made on Cempra’s Phase 3 clinical trial for oral solithromycin in which oral solithromycin was found to be non-inferior to and have a comparable safety and tolerability profile versus oral moxifloxacin for treatment of adult community acquired bacterial pneumonia (CABP). In elderly patients and those with COPD or asthma, compared to moxifloxacin, the number of responders on solithromycin was numerically greater. Late-Breaking Abstract (PA2655), Hall 14-29, Session 277, September 28, 12:50 p.m. CET. An abstract is available from the ERS website at www.erscongress.org.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra’s two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is in Phase 3 clinical development for community acquired bacterial pneumonia (CABP) and is licensed to strategic commercial partner Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain exclusive rights in Japan. Solithromycin has also entered a Phase 3 clinical trial for uncomplicated bacterial urethritis caused by Neisseria gonorrhoeae and chlamydia. Cempra is contracted with BARDA for the development of solithromycin for pediatric use. Three formulations, intravenous, oral capsules and a suspension formulation are in a Phase 1b trial in children from birth to 17 years of age. Taksta™ is Cempra’s second product candidate, which is being developed for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and also being tested in an exploratory study for chronic oral treatment of refractory infections in bones and joints. Both products seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company has also synthesized novel macrolides for non-antibiotic uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Cempra was founded in 2006 and is headquartered in Chapel Hill, N.C. For additional information about Cempra please visit www.cempra.com.
CONTACT: Investor Contact: Robert H. Uhl Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com Media Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com
Help employers find you! Check out all the jobs and post your resume.
